PROFESSIONAL TRAINING AND EXPERIENCE

?      Director of Dermatopathology, Hospital Pathology Associates, 2003 - present
Abbott Northwestern Hospital, Minneapolis, Minnesota

?      Staff Pathologist, Associated Pathologists, 2000-2001
Everett, Washington

?      Dermatopathology Fellowship, Ohio State University, 2002-2003
Columbus, OH

?      Diagnostic Immunohistochemistry Fellowship, PhenoPath Laboratories, 2001-2002
Seattle, WA
 

EDUCATION  

?      Dartmouth Medical School, Hanover, NH, 1991-1996
M.D., June, 1996
Distinguished Student Award, presented annually to a single student by the Department of Pathology

?      Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1993-1994   
Post-Sophomore Fellowship in Pathology

?      University of Washington, Seattle, WA, 1989-1991
Premedical studies, 3.7 GPA

?      Yale University, New Haven, CT, 1982-1986
BA, June 1986
Distinction in the Major of Philosophy
Yale Crew’s Blagden Trophy for excellence and leadership

ACADEMIC APPOINTMENTS

            University of Minnesota Department of Dermatology, 2004-

                      Faculty Teacher of the Year, 2006

Annual award by University of MN Dermatology Residents

          University of Minnesota Department of Pathology, 2006- 

PROFESSIONAL AFFILIATIONS

?      Minnesota Dermatological Society

?      American Academy of Dermatology, Affiliate Member

?      American Society of Dermatopathology

?      Minnesota Medical Association

?      College of American Pathologists, Fellow, Inspector

?      American Society of Clinical Pathologists, Fellow

?      United States and Canadian Academy of Pathology

PROFESSIONAL CERTIFICATIONS

?      Anatomic and Clinical Pathology, September 2000

?      Dermatopathology, September 2003

LICENSURE

?     State of Minnesota - 2002

BIBLIOGRAPHY

PUBLICATIONS 

1. T-cell clonality determination using polymerase chain reaction amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled products.  J Sprouse, RW Werling, D Hanke, C Lakey, L McDonnel, BL Wood, DE Sabath.  American Journal of Clinical Pathology  (2000) 113:838-850.   Recipient of University of Washington Department of Laboratory Medicine’s Strandjord  Clayson Award  for “meritorious research.”

2. Distribution of Tissue Factor Pathway Inhibitor (TFPI) in normal and malignant human tissues.  RW Werling, LR Zacharski, W Kisiel, SP Bajaj, VA Memoli, SM Rousseau.  Thrombosis and Hemostasis, 69 (4) 366-9 (1993).  

3. CDX-2 is a highly sensitive and specific marker of adenocarcinomas of the colorectum and gastrointestinal tract:  an immunohistochemical survey of 426 primary and metastatic carcinomas.  RW Werling, H Yaziji, C Bacchi, AM Gown. American Journal of Surgical Pathology, 2003 Mar;27(3):303-10.

4. Immunohistochemical distinction of invasive from non-invasive breast lesions:  a comparative study of p63 vs. calponin and smooth muscle myosin heavy chain.  RW Werling, H Hwang, H Yaziji, and AM Gown. American Journal of Surgical Pathology, 2003 Jan;27(1):82-90.  

5. HER-2 testing in breast cancer using parallel tissue-based methods.  H Yaziji, LC Goldstein, TS Barry, RW Werling, H Hwang, GK Ellis, JR Gralow, RB Livingston, AM Gown. Journal of the American Medical Association, 2004; 291:1972-1977. 

6. Assessment of T cell clonality via TCR gamma rearrangements in cutaneous T cell-dominant infiltrates using PCR and Single-Stranded DNA Conformational Polymorphism Assay. M Chen, A Deng, AN Crowson, M Srinivasan, K Yearsley, S Jewell, C Morrison, S Long, RW Werling, C Magro. Applied Immunohistochemistry and Molecular Morphology, (in press)

Abstracts/Presentations 

1. Comparative sensitivities of mammaglobin and gross cystic disease fluid protein-15 as immunohistochemical markers of breast carcinoma. RW Werling, H Yaziji, G Fanger, AM Gown. United States and Canadian Academy of Pathology, February 2002, Chicago. 

2. Immunohistochemical distinction of invasive from non-invasive breast lesions: a comparative study of p63 vs. calponin and smooth muscle myosin heavy chain. RW Werling, H Yaziji, H Hwang, AM Gown. United States and Canadian Academy of Pathology, February 2002, Chicago. 

3. Predictive value of HER-2/neu gene status of breast cancer by immunohistochemistry: a survey of 700 tumors.  H Yaziji, L Goldstein, RW Werling, J Wirtala, P Davie, AM Gown. United States and Canadian Academy of Pathology, February 2002, Chicago. 

4. T-cell clonality determination using polymerase chain reaction amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled products.  RW Werling, D Hanke, C Lakey, L McDonnel, BL Wood, DE Sabath. United States and Canadian Academy of Pathology, March 1999, San Francisco. 

5. Technical Comparison of the AxSym CA 15-3 and ACS-180 BR Breast Cancer Tumor Markers. RW Werling and MH Wener.  Acadamy of Clinical Laboratory Physicians and Scientists, June 1998, Boston. Abstract published in the American Journal of Clinical Pathology, 8/98. 

6. Distribution of Tissue Factor Pathway Inhibitor (TFPI) in normal and malignant human tissues. RW Werling, LR Zacharski, W Kisiel, SP Bajaj, VA Memoli, SM Rousseau. American Society of Hematology, 1991, Denver.